Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab

ConclusionsWhile available data have not identified significant risks associated with a single switch between reference and biosimilar infliximab, the studies available currently report on only single switches and were mostly observational studies lacking control arms. Additional data are needed to explore potential switching risks in various populations and scenarios.

https://onlinelibrary.wiley.com/doi/abs/10.1111/apt.14997?af=R

Source: Alimentary Pharmacology and Therapeutics - November 8, 2018 Category: Drugs & Pharmacology Authors: Brian G. Feagan, Gordon Lam, Christopher Ma, Gary R. Lichtenstein Tags: SYSTEMATIC REVIEW Source Type: research